DK3389701T3 - Nucleotidesekvens, der udtrykker et exosomforankrende, protein til anvendelse som vaccine - Google Patents
Nucleotidesekvens, der udtrykker et exosomforankrende, protein til anvendelse som vaccine Download PDFInfo
- Publication number
- DK3389701T3 DK3389701T3 DK17826320.8T DK17826320T DK3389701T3 DK 3389701 T3 DK3389701 T3 DK 3389701T3 DK 17826320 T DK17826320 T DK 17826320T DK 3389701 T3 DK3389701 T3 DK 3389701T3
- Authority
- DK
- Denmark
- Prior art keywords
- exosome
- vaccine
- nucleotide sequence
- anchoring protein
- sequence expressing
- Prior art date
Links
- 238000004873 anchoring Methods 0.000 title 1
- 239000002773 nucleotide Substances 0.000 title 1
- 125000003729 nucleotide group Chemical group 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001191—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464486—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102016000101794A IT201600101794A1 (it) | 2016-10-11 | 2016-10-11 | Sequenza nucleotidica esprimente una proteina ancorante esosomi per uso come vaccino. |
| PCT/IT2017/000223 WO2018069947A1 (en) | 2016-10-11 | 2017-10-11 | Nucleotide sequence expressing an exosome-anchoring protein for use as vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3389701T3 true DK3389701T3 (da) | 2020-08-03 |
Family
ID=58609653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17826320.8T DK3389701T3 (da) | 2016-10-11 | 2017-10-11 | Nucleotidesekvens, der udtrykker et exosomforankrende, protein til anvendelse som vaccine |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11559571B2 (da) |
| EP (1) | EP3389701B1 (da) |
| JP (2) | JP2019536473A (da) |
| KR (1) | KR102620487B1 (da) |
| CN (2) | CN117210480A (da) |
| AU (1) | AU2017343893A1 (da) |
| BR (1) | BR112019007343A2 (da) |
| CA (1) | CA3040035A1 (da) |
| DK (1) | DK3389701T3 (da) |
| ES (1) | ES2809212T3 (da) |
| HU (1) | HUE050492T2 (da) |
| IL (1) | IL265942B2 (da) |
| IT (1) | IT201600101794A1 (da) |
| MX (1) | MX2019004183A (da) |
| NZ (1) | NZ753370A (da) |
| RU (1) | RU2761642C2 (da) |
| SG (1) | SG11201903235XA (da) |
| WO (1) | WO2018069947A1 (da) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT201600101794A1 (it) | 2016-10-11 | 2018-04-11 | St Superiore Di Sanita | Sequenza nucleotidica esprimente una proteina ancorante esosomi per uso come vaccino. |
| IT202000009688A1 (it) | 2020-05-04 | 2021-11-04 | Biovelocita S R L | Proteine di fusione di ancoraggio a esosomi |
| WO2021224429A1 (en) | 2020-05-06 | 2021-11-11 | Biovelocita S.R.L | Exosome-anchoring coronavirus fusion proteins and vaccines |
| IT202000030740A1 (it) | 2020-12-14 | 2022-06-14 | St Superiore Di Sanita | SEQUENZA NUCLEOTIDICA ESPRIMENTE UNA PROTEINA ANCORANTE VESCICOLE EXTRACELLULARI FUSA AD ANTIGENI DI SARS-CoV-2 E RELATIVA PROTEINA DI FUSIONE PER L’USO COME VACCINO |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6534285B1 (en) * | 1984-12-24 | 2003-03-18 | Genentech, Inc. | Molecularly cloned acquired immunodeficiency syndrome polypeptides and their methods of use |
| GB0118532D0 (en) | 2001-07-30 | 2001-09-19 | Isis Innovation | Materials and methods relating to improved vaccination strategies |
| FR2928926B1 (fr) * | 2008-03-18 | 2015-08-21 | Centre Nat Rech Scient | Polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leur utilisation pour la production de compositions immunogenes |
| EP2550298B1 (en) | 2010-03-23 | 2015-07-15 | The Regents of The University of California | Compositions and methods for self-adjuvanting vaccines against microbes and tumors |
| WO2011159814A2 (en) | 2010-06-15 | 2011-12-22 | The Regents Of The University Of California | Novel live recombinant booster vaccine against tuberculosis |
| US10004793B2 (en) | 2014-04-24 | 2018-06-26 | Statens Serum Institut | M.tuberculosis vaccines |
| IT201600101794A1 (it) | 2016-10-11 | 2018-04-11 | St Superiore Di Sanita | Sequenza nucleotidica esprimente una proteina ancorante esosomi per uso come vaccino. |
| IT201600131935A1 (it) | 2016-12-29 | 2018-06-29 | Enea Agenzia Naz Per Le Nuove Tecnologie Lenergia E Lo Sviluppo Economico Sostenibile | Sequenza segnale di proteina vegetale come coadiuvante in vaccini a DNA. |
| US11130787B2 (en) | 2020-06-11 | 2021-09-28 | MBF Therapeutics, Inc. | Alphaherpesvirus glycoprotein d-encoding nucleic acid constructs and methods |
| CN112409496B (zh) | 2020-11-26 | 2021-07-13 | 焦顺昌 | 一种跨膜表达新型冠状病毒抗原s2的融合蛋白、重组载体、重组树突状细胞及其应用 |
-
2016
- 2016-10-11 IT IT102016000101794A patent/IT201600101794A1/it unknown
-
2017
- 2017-10-11 US US16/341,042 patent/US11559571B2/en active Active
- 2017-10-11 AU AU2017343893A patent/AU2017343893A1/en active Pending
- 2017-10-11 HU HUE17826320A patent/HUE050492T2/hu unknown
- 2017-10-11 CA CA3040035A patent/CA3040035A1/en active Pending
- 2017-10-11 EP EP17826320.8A patent/EP3389701B1/en active Active
- 2017-10-11 SG SG11201903235XA patent/SG11201903235XA/en unknown
- 2017-10-11 MX MX2019004183A patent/MX2019004183A/es unknown
- 2017-10-11 RU RU2019114370A patent/RU2761642C2/ru active
- 2017-10-11 BR BR112019007343A patent/BR112019007343A2/pt not_active Application Discontinuation
- 2017-10-11 ES ES17826320T patent/ES2809212T3/es active Active
- 2017-10-11 CN CN202310836753.5A patent/CN117210480A/zh active Pending
- 2017-10-11 WO PCT/IT2017/000223 patent/WO2018069947A1/en active Application Filing
- 2017-10-11 IL IL265942A patent/IL265942B2/en unknown
- 2017-10-11 NZ NZ753370A patent/NZ753370A/en unknown
- 2017-10-11 JP JP2019540142A patent/JP2019536473A/ja active Pending
- 2017-10-11 DK DK17826320.8T patent/DK3389701T3/da active
- 2017-10-11 KR KR1020197013580A patent/KR102620487B1/ko active IP Right Grant
- 2017-10-11 CN CN201780076288.2A patent/CN110049775A/zh active Pending
-
2022
- 2022-03-03 JP JP2022032547A patent/JP7340639B2/ja active Active
-
2023
- 2023-01-20 US US18/157,534 patent/US20230364211A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112019007343A2 (pt) | 2019-10-01 |
| AU2017343893A1 (en) | 2019-05-30 |
| ES2809212T3 (es) | 2021-03-03 |
| RU2019114370A3 (da) | 2021-03-01 |
| IT201600101794A1 (it) | 2018-04-11 |
| MX2019004183A (es) | 2020-09-03 |
| CN110049775A (zh) | 2019-07-23 |
| RU2761642C2 (ru) | 2021-12-13 |
| US20200206329A1 (en) | 2020-07-02 |
| KR102620487B1 (ko) | 2024-01-03 |
| WO2018069947A8 (en) | 2019-07-04 |
| CN117210480A (zh) | 2023-12-12 |
| WO2018069947A1 (en) | 2018-04-19 |
| IL265942B2 (en) | 2023-11-01 |
| HUE050492T2 (hu) | 2020-12-28 |
| US11559571B2 (en) | 2023-01-24 |
| IL265942A (en) | 2019-05-30 |
| IL265942B1 (en) | 2023-07-01 |
| RU2019114370A (ru) | 2020-11-13 |
| JP2019536473A (ja) | 2019-12-19 |
| CA3040035A1 (en) | 2018-04-19 |
| JP7340639B2 (ja) | 2023-09-07 |
| EP3389701A1 (en) | 2018-10-24 |
| EP3389701B1 (en) | 2020-04-29 |
| KR20190079628A (ko) | 2019-07-05 |
| NZ753370A (en) | 2024-01-26 |
| SG11201903235XA (en) | 2019-05-30 |
| JP2022071130A (ja) | 2022-05-13 |
| US20230364211A1 (en) | 2023-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3292137T3 (da) | Proteiner specifikke for cd137 | |
| DK3218392T3 (da) | Makrocykliske peptider, der er anvendelige som immunmodulatorer | |
| DK3461821T3 (da) | Indolcarboxamidforbindelser, der er brugbar som kinasehæmmere | |
| DK3708668T3 (da) | Kunstigt nukleinsyremolekyle til forbedret proteinudtrykkelse | |
| BR112018005406A2 (pt) | métodos para preparar um catalisador. | |
| DK3288573T3 (da) | Onkolytisk adenovirus, der koder for et b7-protein | |
| DK3256853T3 (da) | Forudsigelse af t-celleepitoper, der er egnede til vaccination | |
| BR112017023285A2 (pt) | métodos para preparar um catalisador. | |
| DK3250586T3 (da) | Hidtil ukendte proteiner, som er specifikke for angiogenese | |
| DK3218504T3 (da) | Trisegmenterede arenavira som vaccinevektorer | |
| DK3218519T3 (da) | Multipass-sekvensering | |
| DK3207053T3 (da) | Hidtil ukendte immunogene peptider | |
| DK3097107T3 (da) | Diaryl-makrocykler som modulatorer for proteinkinaser | |
| DK3325487T3 (da) | Formulering til bløde, anticholinerge analoger | |
| DK3323814T3 (da) | (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepan-2-carboxamider som dipeptidylpeptidase i-hæmmere | |
| DK3072835T3 (da) | Fremgangsmåde til fremføring | |
| DK3352625T3 (da) | Reorganiserbar liggestol til flere formål, flere anvendelser | |
| DK3253762T3 (da) | 9h-pyrrolo-dipyridinderivater. | |
| DK3331863T3 (da) | Hidtil ukendte forbindelser som ror-gamma-modulatorer | |
| DK3256462T3 (da) | Substituerede 2-thioimidazolyl-carboxamider som skadedyrsbekæmpelsesmiddel | |
| FR3025438B1 (fr) | Regenerateur de catalyseurs. | |
| DK3389701T3 (da) | Nucleotidesekvens, der udtrykker et exosomforankrende, protein til anvendelse som vaccine | |
| DK3352817T3 (da) | Injektionsapparat, navnlig som auto-injektor | |
| DK3164410T3 (da) | Protein-indvinding | |
| DK3265121T3 (da) | Markørsystem, især for baculovirus-eksprimerede underenhedsantigener |